0.857  -0.033 (-3.69%)		04-24 16:00
Open: 0.835 High: 0.87 Volume: 23,121		Pre. Close: 0.8898 Low: 0.8274 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	2.14	1-year :	2.97
Resists	First :	1.83	Second :	2.54
Pivot price	1.17
Supports	First :	0.68	Second :	0.57
MAs	MA(5) :	0.87	MA(20) :	1.32
	MA(100) :	2.06	MA(250) :	2.77
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	9.4	D(3) :	9.7
RSI	RSI(14): 23.9
52-week	High :	26.4	Low :	0.41

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PRFX ] has closed above bottom band by 27.8%. Bollinger Bands are 118.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	0.87 - 0.88	0.88 - 0.88
Low:	0.81 - 0.82	0.82 - 0.82
Close:	0.85 - 0.86	0.86 - 0.87

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Thu, 18 Apr 2024
PainReform Announces Closing of $4 Million Public Offering - GlobeNewswire

Tue, 16 Apr 2024
PainReform Ltd. Launches $4 Million Public Offering - TipRanks.com - TipRanks

Tue, 09 Apr 2024
PainReform's Non-Opiate Topical Treatment for Post-Surgical - GlobeNewswire

Tue, 02 Apr 2024
PainReform Hits 50% Enrollment Milestone - TipRanks.com - TipRanks

Tue, 02 Apr 2024
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy - Yahoo Finance

Fri, 01 Mar 2024
PRFX Stock Quote Price and Forecast - CNN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	2 (M)
Shares Float	1 (M)
Held by Insiders	4.3 (%)
Held by Institutions	20.9 (%)
Shares Short	16 (K)
Shares Short P.Month	2 (K)

EPS	-7.14
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.19
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-53.9 %
Return on Equity (ttm)	-102.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.88
Qtrly Earnings Growth	0 %
Operating Cash Flow	-7 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.13
PEG Ratio	0
Price to Book value	0.2
Price to Sales	0
Price to Cash Flow	-0.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.